Compare AU
Compare IGRO vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares High Growth Esg ETF (IGRO) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IGRO | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 7 | 83 |
Median incremental investment | $670.06 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,861.04 | $1,437.24 |
Average age group | > 35 | > 35 |
Key Summary
IGRO | CURE | |
|---|---|---|
Strategy | IGRO.AX was created on 2022-08-15 by iShares. The fund's investment portfolio concentrates primarily on target outcome asset allocation. The Fund aims to provide investors with the performance of the various indices of the Underlying Funds | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | iShares Core MSCI Wld Ex Aus ESG ETF (40.70 %) iShares Core MSCI Australia ESG ETF (35.56 %) iShares Core MSCI Wld ex Aus ESG AUHDETF (14.75 %) | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) |
Top 3 industries | Other (99.98 %) Communication Services (0.02 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (47.22 %) Australia (36.23 %) Japan (3.92 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.22 % | 0.45 % |
Key Summary
IGRO | CURE | |
|---|---|---|
Issuer | iShares | Global X |
Tracking index | 34% MSCI Australia IMI Custom ESG Leaders Index - 43% MSCI World Ex Australia Custom ESG Leaders Index - 13% MSCI World Ex Australia Custom ESG Leaders Index AUD Hedged - 10% Other Benchmark - Benchmark TR Net | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.22 % | 0.45 % |
Price | $34.06 | $51.33 |
Size | $10.554 million | $36.301 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.32 % | 4.24 % |
Market | ASX | ASX |
First listed date | 16/08/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IGRO | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 7 | 83 |
Median incremental investment | $670.06 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,861.04 | $1,437.24 |
Average age group | > 35 | > 35 |
Pros and Cons
IGRO | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IGRO | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |